Icaritin enhances sorafenib-induced apoptosis through a mitochondria-dependent pathway

doi:10.5246/jcps.2022.12.078

Abstract

Abstract:

Sorafenib remains the standard systemic treatment for advanced human hepatocellular carcinoma (HCC). However, the low response rate, high recurrence, and high progression limit the therapeutic efficacy. Therefore, a combination therapy strategy was advanced to strengthen the antitumor effects of sorafenib. In the present study, we aimed to evaluate whether icaritin could enhance the inhibitory effects of sorafenib on HCC cells and clarify the underlying mechanism. The cell viability was evaluated via MTT assay, and the synergistic inhibitory effects of sorafenib and icaritin were verified by calculating the combination index (CI). Their combined effects on cell proliferation or apoptosis were investigated using colony formation assay and flow cytometry. Mitochondrial membrane potential (MMP) was detected by flow cytometric assay. The protein expressions associated with the apoptotic pathway were determined by Western blotting analysis. The data demonstrated that sorafenib and icaritin exerted synergistic inhibitory effects on cell viability (CI < 1). Icaritin enhanced the inhibitory effect of sorafenib on colony formation and sorafenib-induced apoptosis of HCC cells. We discovered a reduced level of antiapoptotic Bcl-2 and an elevated level of proapoptotic protein Bax when the cells were exposed to the combination. The effect of cleaved and activated PARP was also enhanced. Cleaved caspase-9 and cleaved caspase-3 were increased markedly in the combination group. Furthermore, the combination of icaritin and sorafenib significantly increased the loss of MMP compared with the single treatment group and induced the release of cytochrome c from the mitochondria to the cytosol. These findings indicated that icaritin could enhance sorafenib-induced cytotoxicity and trigger sorafenib-induced apoptosis through a mitochondria-dependent pathway.

Key words: Sorafenib, Icaritin, Human hepatocellular carcinoma

Supporting:

Axi Shi, Tiantian Shen, Wenbin Xia, Lili Xi, Lijun Wang, Yuhui Wei. Icaritin enhances sorafenib-induced apoptosis through a mitochondria-dependent pathway[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(12): 928-937.

Figures/Tables 7

References 24

[1]	Villanueva, A. Hepatocellular carcinoma. N Engl J. Med. 2019, 380, 1450–1462.
[2]	Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66, 11851–11858.
[3]	Wörns, M.A.; Galle, P.R. HCC therapies—lessons learned. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 447–452.
[4]	Wo, Y.B.; Zhu, D.Y.; Hu, Y.; Wang, Z.Q.; Liu, J.; Lou, Y.J. Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. J. Cell Biochem. 2008, 103, 1536–1550.
[5]	Liao, J.Y.; Liu, Y.; Wu, H.J.; Zhao, M.; Tan, Y.X.; Li, D.; Long, H.; Dai, Y.; Yung, S.; Chan, T.M.; Lu, Q.J. The role of icaritin in regulating Foxp3/IL17a balance in systemic lupus erythematosus and its effects on the treatment of MRL/lpr mice. Clin. Immunol. 2016, 162, 74–83.
[6]	Wang, Z.; Zhang, X.; Wang, H.; Qi, L.; Lou, Y. Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway. Neuroscience. 2007, 145, 911–922.
[7]	Qin, L.; Yao, D.; Zheng, L.Z.; Liu, W.C.; Liu, Z.; Lei, M.; Huang, L.; Xie, X.H.; Wang, X.L.; Chen, Y.; Yao, X.S.; Peng, J.; Gong, H.; Griffith, J.F.; Huang, Y.P.; Zheng, Y.P.; Feng, J.Q.; Liu, Y.; Cheng, C.Y. Phytomolecule icaritin incorporated PLGA/TCP scaffold for steroid-associated osteonecrosis: proof-of-concept for prevention of hip joint collapse in bipedal emus and mechanistic study in quadrupedal rabbits. Biomaterials. 2015, 59, 125–143.
[8]	Yang, X.J.; Xi, Y.M.; Li, Z.J. Icaritin: a novel natural candidate for hematological malignancies therapy. Biomed. Res. Int. 2019, 2019, 4860268.
[9]	Liu, P.; Jin, X.; Lv, H.; Li, J.; Xu, W.; Qian, H.H.; Yin, Z. Icaritin ameliorates carbon tetrachloride-induced acute liver injury mainly because of the antioxidative function through estrogen-like effects. Vitro Cell Dev. Biol. Animal. 2014, 50, 899–908.
[10]	Zhang, W.; Xing, B.; Yang, L.; Shi, J.; Zhou, X. Icaritin attenuates myocardial ischemia and reperfusion injury via anti-inflammatory and anti-oxidative stress effects in rats. Am. J. Chin. Med. 2015, 43, 1083–1097.
[11]	Hao, H.B.; Zhang, Q.; Zhu, H.; Wen, Y.X.; Qiu, D.; Xiong, J.; Fu, X.L.; Wu, Y.Z.; Meng, K.; Li, J. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice. Eur. J. Immunol. 2019, 49, 2235–2244.
[12]	He, J.; Wang, Y.; Duan, F.; Jiang, H.; Chen, M.F.; Tang, S.Y. Icaritin induces apoptosis of HepG2 cells via the JNK₁ signaling pathway independent of the estrogen receptor. Planta Med. 2010, 76, 1834–1839.
[13]	Sun, L.; Chen, W.; Qu, L.; Wu, J.; Si, J. Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P‑glycoprotein expression. Mol. Med. Rep. 2013, 8, 1883–1887.
[14]	Chen, S.H.; Wang, G.; Niu, X.J.; Zhao, J.Y.; Tan, W.X.; Wang, H.B.; Zhao, L.J.; Ge, Y.B. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. 2014, 348, 20–28.
[15]	Keating, G.M. Sorafenib: a review in hepatocellular carcinoma. Target. Oncol. 2017, 12, 243–253.
[16]	Liu, J.X.; Cui, X.P.; Qu, L.S.; Hua, L.; Wu, M.M.; Shen, Z.Y.; Lu, C.H.; Ni, R.Z. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. Exp. Mol. Pathol. 2016, 101, 58–65.
[17]	Chen, W.L.; Hsieh, C.L.; Chen, J.H.; Huang, C.S.; Chen, W.T.; Kuo, Y.C.; Chen, C.Y.; Hsu, F.T. Amentoflavone enhances sorafenib-induced apoptosis through extrinsic and intrinsic pathways in sorafenib-resistant hepatocellular carcinoma SK-Hep1 cells in vitro. Oncol. Lett. 2017, 14, 3229–3234.
[18]	Wang, H.; Zhang, C.; Chi, H.; Meng, Z. Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. Mol. Med. Rep. 2018, 17, 8101–8110.
[19]	Feng, X.Q.; Rong, L.W.; Wang, R.X.; Zheng, X.L.; Zhang, L.; Zhang, L.; Lin, Y.; Wang, X.; Li, Z.P. Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation. Oncol. Lett. 2018, 16, 648–653.
[20]	Yu, Z.; Guo, J.F.; Hu, M.Y.; Gao, Y.Q.; Huang, L. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma. ACS Nano. 2020, 14, 4816–4828.
[21]	Pan, X.W.; Li, L.; Huang, Y.; Huang, H.; Xu, D.F.; Gao, Y.; Chen, L.; Ren, J.Z.; Cao, J.W.; Hong, Y.; Cui, X.G. Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy. Oncol. Rep. 2016, 35, 334–342.
[22]	Tait, S.W.; Green, D.R. Mitochondrial regulation of cell death. Cold Spring Harb. Perspect. Biol. 2013, 5, a008706.
[23]	International, B.R. Retracted: apoptosis and molecular targeting therapy in cancer. Biomed Res. Int. 2020, 2020, 2451249.
[24]	Antonsson, B.; Montessuit, S.; Sanchez, B.; Martinou, J.C. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J. Biol. Chem. 2001, 276, 11615–11623.